|
Daily Medical Update
Erectile Dysfunction (Cardiovascular risk marker, PDE5i)
Wednesday, March 04, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Journal (2025) - Systematic Review/Meta-Analysis
Key Findings
- PDE5 inhibitor exposure improved endothelial function outcomes versus controls, with stronger benefit signals in cardiometabolic subgroups.
- Pooled analyses showed reduced vascular stiffness and improved flow-mediated outcomes, supporting a systemic vascular effect beyond erectile symptom control.
📋 Practice Implication: Use a new ED complaint as a trigger to intensify ASCVD risk workup (BP, lipids, diabetes control, smoking) rather than treating sexual symptoms in isolation.
|
Journal (2025) - Systematic Review/Meta-Analysis
Key Findings
- Across diabetic ED trials, PDE5 inhibitors increased erectile-response and successful-intercourse outcomes versus placebo.
- Adverse events were usually mild and dose-related, and discontinuation remained low compared with placebo groups.
📋 Practice Implication: In men with T2DM and ED, start with an adequate-dose PDE5 inhibitor trial before specialist referral or procedural options.
|
Journal (2026) - Randomized Controlled Trial
Key Findings
- In hypogonadal men with T2DM, testosterone therapy produced greater erectile-function score gains versus control treatment.
- Sexual desire and treatment satisfaction increased with testosterone normalization without a major short-term serious safety signal.
📋 Practice Implication: For PDE5 partial responders with symptoms of hypogonadism, confirm morning testosterone and consider guideline-concordant testosterone replacement when deficiency is documented.
|
European Urology (2025) - Practice Guideline
Key Findings
- Guideline recommendations maintain lifestyle/risk-factor correction plus PDE5 inhibitors as the core first-line ED strategy.
- The update emphasizes formal cardiovascular risk stratification before escalation to invasive or regenerative therapies.
📋 Practice Implication: Implement a standardized ED visit pathway in primary care: cardiovascular risk stratification first, then stepwise evidence-based therapy escalation.
|
|
Recent evidence reinforces erectile dysfunction as both a treatable symptom and a cardiovascular risk signal in primary care. High-value updates support a structured first-line approach with PDE5 inhibitors in diabetes-related ED, targeted hypogonadism evaluation when response is incomplete, and proactive vascular-risk management triggered by ED presentations.
|
|